Dorsey Wright & Associates Buys New Holdings in argenex SE $ARGX

Dorsey Wright & Associates purchased a new position in shares of argenex SE (NASDAQ:ARGX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,479 shares of the company’s stock, valued at approximately $1,244,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Abound Wealth Management lifted its holdings in shares of argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares during the period. Sound Income Strategies LLC bought a new stake in argenex in the fourth quarter valued at about $28,000. Ameriflex Group Inc. bought a new stake in argenex in the third quarter valued at about $32,000. Sunbelt Securities Inc. acquired a new position in argenex in the third quarter worth about $36,000. Finally, Aventura Private Wealth LLC acquired a new position in argenex in the fourth quarter worth about $38,000. Institutional investors own 60.32% of the company’s stock.

argenex Stock Down 1.6%

Shares of NASDAQ ARGX opened at $877.72 on Friday. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The firm’s 50-day simple moving average is $822.61 and its 200 day simple moving average is $810.57. The company has a market cap of $54.59 billion, a price-to-earnings ratio of 39.08, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The firm had revenue of $1.31 billion during the quarter. On average, equities analysts expect that argenex SE will post 26.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada decreased their price objective on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Guggenheim increased their target price on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Oppenheimer cut their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. HC Wainwright boosted their price target on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Citizens Jmp upped their price target on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,019.50.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.